Tuesday, February 22, 2022

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Is World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Technology

 Lexaria Bioscience Corp. (NASDAQ: LEXX) commented on an independent study headed by lead research scientist Dr. Richard van Breeman, which discovered that cannabinoids can block cellular entry of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its emerging variants. The study showed that smoking and vaping are likely ineffective measures, whereas oral delivery methods are. “As a company, Lexaria is already actively exploring and researching DehydraTECH(TM)-enabled cannabinoid formulations across various potential therapeutic applications, including oral formulations that are being prepared for registered clinical trials as a possible new pharmaceutical product,” reads a recent article. “In response to the study, Chris Bunka, CEO of Lexaria Bioscience, said, ‘Lexaria has led the conversation for years related to oral delivery of cannabinoids and is a world leader through its pioneering drug delivery technology, DehydraTECH, in more effective delivery of cannabinoids to the human bloodstream through oral means.’… Lexaria previously announced in June 2021 that the DehydraTECH-enabled remdesivir and ebastine effectively inhibited the SARS-CoV-2 virus.”

To view the full article, visit https://ibn.fm/8RkZK

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from one to two hours to minutes, and mask unwanted tastes. The technology is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html